Pacific Biosciences of California (PACB) Peer Comparison

$1.35

$0.05 (3.85%)

As on 04-Sep-2026 19:34EDT

Market cap

$420 Mln

Revenue (TTM)

$159 Mln

P/E Ratio

--

P/B Ratio

170.7

Div. Yield

0 %

Edit

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	420	12,650	10,638	9,762	9,459
Revenue ($ Mln)	159	1,505	613	2,589	785
Net Profit ($ Mln)	-131.39	160.59	-188.05	222.40	41.54
Net Margin (%)	-82.49	10.67	-30.68	8.59	5.29
RoE (%)	--	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	232.78
Price-To-Book	170.66	8.31	15.27	1.36	4.62

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	159.27	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	101.98	483.98	127.96	1,245.50	384.30
Gross Profit	50.67	942.44	393.22	1,343.60	347.62
Operating Expenses	219.83	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-162.54	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-130.56	203.83	-192.83	350.40	52.15
Provision for Tax	0.83	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-131.39	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	-33.21	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	716.26	210.18	135.71	2,116.80	705.49
Current Liabilities	68.81	233.78	102.33	961.30	132.66
Total Liabilities	784.08	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	413.21	630.60	404.74	7,231.50	1,749.63
Current Assets	338.64	1,344.12	515.78	3,020.50	1,200.55
Total Assets	784.08	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	706.13	212.71	102.84	1,203.70	690.94
Net Current Assets	269.83	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-111.21	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	115.45	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	3.43	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-56.20	11.76	-22.53	8.98	1.79
ROE (%)	-213.45	10.86	-28.10	3.04	1.97
ROA (%)	-15.40	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-79.56	13.63	-30.58	-5.99	9.87
Net Margin (%)	-82.49	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	2.02	17.55	41.55	1.37	16.49
EBIT Growth (%)	75.47	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	75.04	8.72	-102.66	-30.32	400.42
EPS Growth (%)	75.91	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-152.19	17.33	-12.65	2.19	2.16

Valuation Ratios

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-1.03	68.93	-34.59	--	189.42
Price / Book Value	105.55	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-30.56	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	-19.40	0.00	0.00	0.11	0.26
Short term debt to equity ratio	-0.04	0.01	0.00	0.06	0.01
Current Ratio	4.92	5.75	5.04	3.14	9.05
Quick Ratio	4.03	3.86	4.46	2.33	7.64
Interest Coverage	-16.81	157.91	-38.31	8.18	1.92

Operating Efficiency Ratios

	Pacific Biosciences of California (PACB)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	19.53	12.65	22.67	17.06	20.09
Asset Turnover	0.19	0.74	0.59	0.24	0.26
Receivable days	71.87	46.54	60.95	65.39	72.41
Inventory Days	180.47	331.92	193.84	221.09	146.53
Payable days	62.41	26.16	60.19	37.02	29.05
Cash Conversion Cycle	189.94	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly